Trial Profile
A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms INFUS-ON
- Sponsors US WorldMeds
- 08 Aug 2023 Planned End Date changed from 1 Sep 2021 to 1 Dec 2023.
- 27 Apr 2023 Results assessing long-term safety and efficacy of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in Parkinson's disease (PD) patients treated in United States (US) settings, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 16 Sep 2020 Results evaluating the efficacy of apomorphine infusion in reducing OFF time during the hours of pump use in PD patients presented at the 24th International Congress of Parkinson's Disease and Movement Disorders